Literature DB >> 20198462

Pancreatic cancer: pathobiology, treatment options, and drug delivery.

Jing Li1, M Guillaume Wientjes, Jessie L-S Au.   

Abstract

Pancreatic cancer is the fourth leading cause of cancer-related deaths in the USA. The high mortality rate is partly due to lack of effective treatments. This review summarizes the pathobiology and current treatment options for pancreatic cancer. Moreover, the review discusses the opportunities of developing novel therapies for pancreatic cancer provided by the progress in understanding the genetic mutations, tumor microenvironment, cancer stem cells, and drug delivery.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20198462      PMCID： PMC2844509          DOI： 10.1208/s12248-010-9181-5

Source DB:  PubMed          Journal:  AAPS J        ISSN： 1550-7416            Impact factor:   4.009


  110 in total

1.  Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer.

Authors:  Lillian L Siu; Ahmad Awada; Chris H Takimoto; Martine Piccart; Brian Schwartz; Tom Giannaris; Chetan Lathia; Oana Petrenciuc; Malcolm J Moore
Journal:  Clin Cancer Res       Date:  2006-01-01       Impact factor: 12.531

Review 2.  Gene therapy developments for pancreatic cancer.

Authors:  Madhumita Bhattacharyya; Nick R Lemoine
Journal:  Best Pract Res Clin Gastroenterol       Date:  2006-04       Impact factor: 3.043

3.  Abrogation of the Rb/p16 tumor-suppressive pathway in virtually all pancreatic carcinomas.

Authors:  M Schutte; R H Hruban; J Geradts; R Maynard; W Hilgers; S K Rabindran; C A Moskaluk; S A Hahn; I Schwarte-Waldhoff; W Schmiegel; S B Baylin; S E Kern; J G Herman
Journal:  Cancer Res       Date:  1997-08-01       Impact factor: 12.701

4.  Surgery versus radiochemotherapy for resectable locally invasive pancreatic cancer: final results of a randomized multi-institutional trial.

Authors:  Ryuichiro Doi; Masayuki Imamura; Ryo Hosotani; Toshihide Imaizumi; Takashi Hatori; Ken Takasaki; Akihiro Funakoshi; Hideyuki Wakasugi; Takehide Asano; Shoichi Hishinuma; Yoshiro Ogata; Makoto Sunamura; Koji Yamaguchi; Masao Tanaka; Sonshin Takao; Takashi Aikou; Koichi Hirata; Hiroyuki Maguchi; Koichi Aiura; Tatsuya Aoki; Akira Kakita; Makoto Sasaki; Masahiko Ozaki; Satoru Matsusue; Shunichi Higashide; Hideki Noda; Seiyo Ikeda; Shunzo Maetani; Shigeaki Yoshida
Journal:  Surg Today       Date:  2008-10-29       Impact factor: 2.549

5.  Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial.

Authors:  William Small; Jordan Berlin; Gary M Freedman; Theodore Lawrence; Mark S Talamonti; Mary F Mulcahy; A Bapsi Chakravarthy; Andre A Konski; Mark M Zalupski; Philip A Philip; Timothy J Kinsella; Nipun B Merchant; John P Hoffman; Al B Benson; Steven Nicol; Rong M Xu; John F Gill; Cornelius J McGinn
Journal:  J Clin Oncol       Date:  2008-02-20       Impact factor: 44.544

6.  Gemcitabine combined with gefitinib in patients with inoperable or metastatic pancreatic cancer: a phase II Study of the Hellenic Cooperative Oncology Group with biomarker evaluation.

Authors:  George Fountzilas; Mattheos Bobos; Anna Kalogera-Fountzila; Nikolaos Xiros; Samuel Murray; Helena Linardou; Georgia Karayannopoulou; Angelos K Koutras; Dimitrios Bafaloukos; Epaminondas Samantas; Christos Christodoulou; Theofanis Economopoulos; Konstantine T Kalogeras; Paris Kosmidis
Journal:  Cancer Invest       Date:  2008-10       Impact factor: 2.176

7.  Vascular normalization in Rgs5-deficient tumours promotes immune destruction.

Authors:  Juliana Hamzah; Manfred Jugold; Fabian Kiessling; Paul Rigby; Mitali Manzur; Hugo H Marti; Tamer Rabie; Sylvia Kaden; Hermann-Josef Gröne; Günter J Hämmerling; Bernd Arnold; Ruth Ganss
Journal:  Nature       Date:  2008-04-16       Impact factor: 49.962

8.  Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate.

Authors:  Caio M Rocha Lima; Mark R Green; Robert Rotche; Wilson H Miller; G Mark Jeffrey; Laura A Cisar; Adele Morganti; Nicoletta Orlando; Gabriela Gruia; Langdon L Miller
Journal:  J Clin Oncol       Date:  2004-09-15       Impact factor: 44.544

9.  Survival and prognostic factor analysis in patients with metastatic pancreatic endocrine carcinomas.

Authors:  Jonathan Strosberg; Nancy Gardner; Larry Kvols
Journal:  Pancreas       Date:  2009-04       Impact factor: 3.327

10.  Phase 2 trial of oral S-1 combined with low-dose cisplatin for unresectable advanced pancreatic cancer.

Authors:  Shinomi Ina; Masaji Tani; Manabu Kawai; Seiko Hirono; Motoki Miyazawa; Ryohei Nishioka; Yoichi Fujita; Hiroki Yamaue
Journal:  Anticancer Res       Date:  2008 Jul-Aug       Impact factor: 2.480
View more
  51 in total

Review 1.  Improving delivery and efficacy of nanomedicines in solid tumors: role of tumor priming.

Authors:  Jie Wang; Ze Lu; Yue Gao; M Guillaume Wientjes; Jessie L-S Au
Journal:  Nanomedicine (Lond)       Date:  2011-11       Impact factor: 5.307

Review 2.  Delivery of cancer therapeutics to extracellular and intracellular targets: Determinants, barriers, challenges and opportunities.

Authors:  Jessie L-S Au; Bertrand Z Yeung; Michael G Wientjes; Ze Lu; M Guillaume Wientjes
Journal:  Adv Drug Deliv Rev       Date:  2015-12-11       Impact factor: 15.470

3.  Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors.

Authors:  Benjamin Diop-Frimpong; Vikash P Chauhan; Stephen Krane; Yves Boucher; Rakesh K Jain
Journal:  Proc Natl Acad Sci U S A       Date:  2011-01-31       Impact factor: 11.205

4.  The Id3/E47 axis mediates cell-cycle control in human pancreatic ducts and adenocarcinoma.

Authors:  Seung-Hee Lee; Ergeng Hao; Alice Kiselyuk; James Shapiro; David J Shields; Andrew Lowy; Fred Levine; Pamela Itkin-Ansari
Journal:  Mol Cancer Res       Date:  2011-04-15       Impact factor: 5.852

5.  Contribution of microRNAs in understanding the pancreatic tumor microenvironment involving cancer associated stellate and fibroblast cells.

Authors:  Shadan Ali; Raagini Suresh; Sanjeev Banerjee; Bin Bao; Zhihong Xu; Jeremy Wilson; Philip A Philip; Minoti Apte; Fazlul H Sarkar
Journal:  Am J Cancer Res       Date:  2015-02-15       Impact factor: 6.166

6.  MicroRNA-148b and microRNA-152 reactivate tumor suppressor genes through suppression of DNA methyltransferase-1 gene in pancreatic cancer cell lines.

Authors:  Masoumeh Azizi; Ladan Teimoori-Toolabi; Mohsen Karimi Arzanani; Kayhan Azadmanesh; Pezhman Fard-Esfahani; Sirous Zeinali
Journal:  Cancer Biol Ther       Date:  2014-01-21       Impact factor: 4.742

Review 7.  The challenge of pancreatic cancer therapy and novel treatment strategy using engineered mesenchymal stem cells.

Authors:  M R Moniri; L-J Dai; G L Warnock
Journal:  Cancer Gene Ther       Date:  2014-01-03       Impact factor: 5.987

8.  EGCG inhibits growth of human pancreatic tumors orthotopically implanted in Balb C nude mice through modulation of FKHRL1/FOXO3a and neuropilin.

Authors:  Sharmila Shankar; Luke Marsh; Rakesh K Srivastava
Journal:  Mol Cell Biochem       Date:  2012-09-13       Impact factor: 3.396

9.  Generation of an in vitro 3D PDAC stroma rich spheroid model.

Authors:  Matthew J Ware; Vazrik Keshishian; Justin J Law; Jason C Ho; Carlos A Favela; Paul Rees; Billie Smith; Sayeeduddin Mohammad; Rosa F Hwang; Kimal Rajapakshe; Cristian Coarfa; Shixia Huang; Dean P Edwards; Stuart J Corr; Biana Godin; Steven A Curley
Journal:  Biomaterials       Date:  2016-09-02       Impact factor: 12.479

Review 10.  Differential role of Hedgehog signaling in human pancreatic (patho-) physiology: An up to date review.

Authors:  Eckhard Klieser; Stefan Swierczynski; Christian Mayr; Tarkan Jäger; Johanna Schmidt; Daniel Neureiter; Tobias Kiesslich; Romana Illig
Journal:  World J Gastrointest Pathophysiol       Date:  2016-05-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.